Scopus h-index:19
- Home
- Profiles
Video Visit Available
Accepting New Patients
Mount Sinai Doctors
Video Visit Available
Accepting New PatientsGene Im, MD
Liver Transplantation
RMTI Liver Disease
212-241-0034
- About Me
- Clinical Focus
- Video
- Education & Certifications
- Research
- Locations
- Insurance
- Publications
- Patient Experience Rating
- Industry Relationships
About Me
Dr. Gene Y Im is an Assistant Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He earned his B.A. from the University of California, Berkeley, graduating with honors. He completed his Internal Medicine residency and fellowship in Gastroenterology at Winthrop-University Hospital, the primary teaching affiliate for the SUNY Stony Brook School of Medicine. He then completed an advanced fellowship in Transplant Hepatology at the Mount Sinai Medical Center. He is currently the Associate Program Director of the Transplant Hepatology fellowship and RSS course director of the Division of Liver Diseases at Mount Sinai.
Dr. Im’s areas of clinical interest include cirrhosis, acute/chronic liver diseases, portal hypertension, liver biopsy, quality improvement, endoscopy, inpatient care of liver patients and liver transplantation.
His research program focuses on alcoholic hepatitis and liver disease, including early liver transplantation for alcoholic hepatitis, portal hypertension, liver biopsy and outcomes-based research.
Dr. Im is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. He is also a member of the American Association for the Study of Liver Diseases.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Research Topics
Hepatitis C Virus, Liver, Transplantation
About Me
Dr. Gene Y Im is an Assistant Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He earned his B.A. from the University of California, Berkeley, graduating with honors. He completed his Internal Medicine residency and fellowship in Gastroenterology at Winthrop-University Hospital, the primary teaching affiliate for the SUNY Stony Brook School of Medicine. He then completed an advanced fellowship in Transplant Hepatology at the Mount Sinai Medical Center. He is currently the Associate Program Director of the Transplant Hepatology fellowship and RSS course director of the Division of Liver Diseases at Mount Sinai.
Dr. Im’s areas of clinical interest include cirrhosis, acute/chronic liver diseases, portal hypertension, liver biopsy, quality improvement, endoscopy, inpatient care of liver patients and liver transplantation.
His research program focuses on alcoholic hepatitis and liver disease, including early liver transplantation for alcoholic hepatitis, portal hypertension, liver biopsy and outcomes-based research.
Dr. Im is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. He is also a member of the American Association for the Study of Liver Diseases.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Research Topics
Hepatitis C Virus, Liver, Transplantation
About Me
Dr. Gene Y Im is an Assistant Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He earned his B.A. from the University of California, Berkeley, graduating with honors. He completed his Internal Medicine residency and fellowship in Gastroenterology at Winthrop-University Hospital, the primary teaching affiliate for the SUNY Stony Brook School of Medicine. He then completed an advanced fellowship in Transplant Hepatology at the Mount Sinai Medical Center. He is currently the Associate Program Director of the Transplant Hepatology fellowship and RSS course director of the Division of Liver Diseases at Mount Sinai.
Dr. Im’s areas of clinical interest include cirrhosis, acute/chronic liver diseases, portal hypertension, liver biopsy, quality improvement, endoscopy, inpatient care of liver patients and liver transplantation.
His research program focuses on alcoholic hepatitis and liver disease, including early liver transplantation for alcoholic hepatitis, portal hypertension, liver biopsy and outcomes-based research.
Dr. Im is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. He is also a member of the American Association for the Study of Liver Diseases.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Research Topics
Hepatitis C Virus, Liver, Transplantation
Clinical Focus
- Alcoholic Liver Disease
- Autoimmune Liver Disease
- Chronic Liver Disease
- Cirrhosis
- Colonoscopy
- Endoscopic Band Ligation
- Esophageal Varices
- Gilbert's Syndrome
- Hemochromatosis
Show More
- Alcoholic Liver Disease
- Autoimmune Liver Disease
- Chronic Liver Disease
- Cirrhosis
- Colonoscopy
- Endoscopic Band Ligation
- Esophageal Varices
- Gilbert's Syndrome
- Hemochromatosis
- Hepatitis B
- Hepatitis C
- Liver Abscess
- Liver Biopsy
- Liver Function Test
- Liver Transplant
- Toxic Hepatitis
- Upper GI Endoscopy
Video
Education
MD, New York Medical College
Residency, Internal Medicine
Winthrop University Hospital
Fellowship, Gastroenterology
Winthrop University Hospital
Fellowship, Transplant Hepatology
The Mount Sinai Hospital
Research
Early liver transplantation for severe alcoholic hepatitis has recently been demonstrated to be a feasible and effective therapy for highly selected patients who fail medical therapy and violate the so-called “6 month rule,” using a rigorous evaluation program. Here at Mount Sinai, we are leading the North American experience of early liver transplantation as a rescue therapy for selected patients with severe alcoholic hepatitis. Particular areas of interest include patient selection, outcomes, burden on organ supply and alcohol relapse. Translational collaborations are being planned with the Alcoholic Liver Disease Research Center at Mount Sinai to further elucidate the pathogenesis of alcoholic hepatitis. Future clinical trials to evaluate therapies with less side-effects, more targeted therapies or those aimed hepatic regeneration are needed.
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- RMTI Liver Disease5 East 98th Street, 12th Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
- RMTI Liver Transplantation5 East 98th Street, 12th Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
- Mount Sinai Doctors Brooklyn Heights300 Cadman Plaza West, 18th Floor, Brooklyn, NY, 11201
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:33
Review Article:10
Comment/Debate:2
Letter:5
Recent Artifacts
- Emerging Biomarkers in Alcohol-associated Hepatitis
- Early Liver Transplantation for Severe Alcohol-Associated Hepatitis and a History of Prior Liver Decompensation
- Reply
- Standardising early liver transplantation for severe alcohol-related hepatitis
- Artificial intelligence to identify harmful alcohol use after early liver transplant for alcohol-associated hepatitis
- The Practice of Retransplantation for Recurrent Alcohol-associated Liver Disease in the United States Is Uncommon with Acceptable Outcomes
- Patterns of Alcohol Use After Early Liver Transplantation for Alcoholic Hepatitis
- Extensive Health Care Utilization and Costs of an Early Liver Transplantation Program for Alcoholic Hepatitis
- An Assessment of the Psychosocial Evaluation for Early Liver Transplantation in Patients With Acute Alcoholic Hepatitis in the Context of Alcohol Use Disorder, a Case-Control Study
- Joining the Fight: Enhancing Alcohol Treatment Education in Hepatology
Patient Experience Rating
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
4.9 out of 5
Care Provider’s Concern
5 out of 5
Likelihood to Recommend Care Provider
4.9 out of 5
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Im did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.